Original Research
The aim of this prospective study is to evaluate the efficacy and activity of the different oncological treatments in patients with HR+/HER– metastatic breast cancer progressing to CDK4/6i therapy in a real-world setting.
Review
This review summarizes the background and latest evidence for the use of palbociclib, an oral, first-in-class, highly selective cyclin-dependent kinase 4/6 inhibitor, in advanced breast cancer, with a focus on some of the unanswered questions about the performance of this agent in clinical practice.
